JP2004513081A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004513081A5 JP2004513081A5 JP2002520896A JP2002520896A JP2004513081A5 JP 2004513081 A5 JP2004513081 A5 JP 2004513081A5 JP 2002520896 A JP2002520896 A JP 2002520896A JP 2002520896 A JP2002520896 A JP 2002520896A JP 2004513081 A5 JP2004513081 A5 JP 2004513081A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- binding agent
- selective binding
- nnt
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 description 37
- 238000000034 method Methods 0.000 description 24
- 239000011230 binding agent Substances 0.000 description 19
- 102100029391 Cardiotrophin-like cytokine factor 1 Human genes 0.000 description 14
- 101710107109 Cardiotrophin-like cytokine factor 1 Proteins 0.000 description 14
- 239000012634 fragment Substances 0.000 description 14
- 239000003112 inhibitor Substances 0.000 description 12
- 229920001184 polypeptide Polymers 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 208000026935 allergic disease Diseases 0.000 description 7
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical group 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22643600P | 2000-08-18 | 2000-08-18 | |
| US09/931,704 US6849260B2 (en) | 2000-08-18 | 2001-08-16 | Methods and compositions for treating IgE-related disease using NNT-1 inhibitors |
| PCT/US2001/025906 WO2002015977A2 (en) | 2000-08-18 | 2001-08-17 | Methods and compositions for treating ige-related disease using nnt-1 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004513081A JP2004513081A (ja) | 2004-04-30 |
| JP2004513081A5 true JP2004513081A5 (enExample) | 2006-01-05 |
Family
ID=26920541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002520896A Pending JP2004513081A (ja) | 2000-08-18 | 2001-08-17 | ＮＮＴ−１インヒビターを使用してＩｇＥ関連疾患を治療するための方法および組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US6849260B2 (enExample) |
| EP (1) | EP1309374A2 (enExample) |
| JP (1) | JP2004513081A (enExample) |
| AU (2) | AU2001283451A1 (enExample) |
| CA (1) | CA2419274A1 (enExample) |
| MX (1) | MXPA03001434A (enExample) |
| WO (1) | WO2002015977A2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006076288A2 (en) * | 2005-01-11 | 2006-07-20 | Five Prime Therapeutics, Inc. | Dna constructs for long-term expression of intravascularly injected naked dna |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100365064B1 (ko) | 1994-10-17 | 2003-04-11 | 훽스트파마슈티칼스앤드케미칼스가부시키가이샤 | I형알레르기성질환의예방및치료제 |
| EP0839155B1 (en) | 1995-07-17 | 2004-10-13 | Medivir UK Ltd | CYSTEINE PROTEASE INHIBITORS FOR USE IN TREATMENT OF IgE MEDIATED ALLERGIC DISEASES |
| US5741772A (en) | 1997-02-03 | 1998-04-21 | Amgen Inc. | Neurotrophic factor NNT-1 |
| IL154543A0 (en) | 1997-02-03 | 2003-09-17 | Amgen Inc | The neurotrophic factor nnt-1 |
| CA2295326A1 (en) | 1997-06-30 | 1999-01-07 | Human Genome Sciences, Inc. | Cardiotrophin-like cytokine |
| GB9913327D0 (en) | 1999-06-08 | 1999-08-11 | Smithkline Beecham Biolog | Vaccine |
-
2001
- 2001-08-16 US US09/931,704 patent/US6849260B2/en not_active Expired - Fee Related
- 2001-08-17 AU AU2001283451A patent/AU2001283451A1/en not_active Abandoned
- 2001-08-17 WO PCT/US2001/025906 patent/WO2002015977A2/en not_active Ceased
- 2001-08-17 MX MXPA03001434A patent/MXPA03001434A/es not_active Application Discontinuation
- 2001-08-17 CA CA002419274A patent/CA2419274A1/en not_active Abandoned
- 2001-08-17 JP JP2002520896A patent/JP2004513081A/ja active Pending
- 2001-08-17 EP EP01962255A patent/EP1309374A2/en not_active Withdrawn
-
2005
- 2005-11-14 AU AU2005232321A patent/AU2005232321A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU780454B2 (en) | Methods and compositions for modulating cell proliferation and cell death | |
| JP4313531B2 (ja) | 第ＩＸ因子／第ＩＸａ因子の抗体および抗体誘導体 | |
| JP4741242B2 (ja) | 新脈管形成を調節するα５β１インテグリンへのキメラ及びヒト化抗体 | |
| US8017116B2 (en) | Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis | |
| MXPA02010059A (es) | Metodo para administrar un anticuerpo. | |
| CA2189015A1 (en) | Methods and compositions for the treatment of glomerulonephritis and other inflammatory diseases | |
| JP2004517611A5 (enExample) | ||
| CN106163556A (zh) | 基质金属蛋白酶底物和其它可切割部分及其使用方法 | |
| JP2007536932A5 (enExample) | ||
| JP2012531902A (ja) | ポリペプチドおよび治療の方法 | |
| RU2003126168A (ru) | Терапевтические связывающие молекулы | |
| CN108026170A (zh) | 抗cd71抗体、可活化抗cd71抗体及其使用方法 | |
| AU2011204349A1 (en) | Plasma kallikrein binding proteins | |
| JP2004507559A5 (enExample) | ||
| WO1996023071A3 (en) | MONOCLONAL ANTIBODIES SPECIFIC FOR DIFFERENT EPITOPES OF HUMAN gp39 AND METHODS FOR THEIR USE IN DIAGNOSIS AND THERAPY | |
| JP2013523190A5 (enExample) | ||
| JP2022524588A5 (enExample) | ||
| RU2009149294A (ru) | Антиген-связывающие белки, нацеленные на orf0657n s.aureus | |
| RU2006140407A (ru) | Антитела к гликопротеину vi и способы продуцирования и использования этих антител | |
| CN103282384A (zh) | 复合药物组合物以及对泌尿生殖系统障碍进行治疗的方法 | |
| JP2003504045A5 (enExample) | ||
| JP2021508366A (ja) | 気分障害の治療及び診断のための抗−配列類似性１９を持つファミリー、メンバーａ５抗体の用途 | |
| AU756677B2 (en) | Anti-TNFalpha antibodies in therapy of asthma | |
| US20020044936A1 (en) | Method of inhibiting angiogenesis and tumor growth and preventing tumor growth and metastases | |
| JP2009524428A5 (enExample) |